¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Vascular Endothelial Growth Factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • vascular disease
    Ç÷°üº´
  • vascular disorder
    Ç÷°üÀå¾Ö
  • vascular fragility
    Ç÷°üÃë¾à¼º
  • vascular lamina
    ¸Æ°üÆÇ
  • vascular layer
    1. ¸Æ°üÃþ 2. Ç÷°üÃþ
  • vascular murmur
    Ç÷°üÀâÀ½
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • vascular purpura
    Ç÷°üÀÚ»ö¹Ý
  • vascular reflex
    Ç÷°ü¹Ý»ç
  • vascular resistance
    Ç÷°üÀúÇ×
  • vascular ring
    Ç÷°ü°í¸®, Ç÷°ü·û
  • vascular sclerosis
    µ¿¸Æ°æÈ­Áõ
  • vascular spider
    °Å¹Ì¸ð¾çÇ÷°ü
  • vascular system
    Ç÷°ü°èÅë, Ç÷°ü°è
  • vascular tone
    Ç÷°ü±äÀåµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • vascular cell adhesion molecule
    Ç÷°ü¼¼Æ÷À¯ÂøºÐÀÚ
  • reticulate vascular nevus
    ±×¹°Ç÷°ü¸ð¹Ý
  • peripheral vascular resistance
    ¸»ÃÊÇ÷°üÀúÇ×
  • pulmonary vascular resistance
    ÇãÆÄÇ÷°üÀúÇ×, ÆóÇ÷°üÀúÇ×
  • vascular purpura
    Ç÷°üÀÚ»ö¹Ý
  • vascular reflex
    Ç÷°ü¹Ý»ç
  • vascular resistance
    Ç÷°üÀúÇ×
  • vascular ring
    Ç÷°ü°í¸®
  • vascular sclerosis
    (¢¡arteriosclerosis) µ¿¸Æ°æÈ­Áõ
  • vascular spider
    °Å¹ÌÇ÷°ü
  • vascular strip
    Ç÷°ü¶ì
  • vascular system
    Ç÷°ü°èÅë
  • vascular tone
    Ç÷°ü±äÀåµµ
  • vascular
    ¸Æ°ü-, Ç÷°ü-
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • Growth folic acid in
    ¼ºÀå(à÷íþ)¿°»ê(ç¤ß«)¿°
  • Growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • Growth hormone-inhibiting hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó¾ïÁ¦(åäð¤)È£¸£¸ó
  • Growth hormone-releasing hormone
    ¼ºÀå(à÷íþ)È£¸£¸óºÐºñ(ÝÂÝô)È£¸£¸ó
  • Growth inducers
    ¼ºÀåÀ¯¹ßÀÎÀÚ(à÷íþë¯Û¡ì×í­)
  • Growth periods
    ¼ºÀå±â°£(à÷íþÑ¢Êà)
  • IGF-I(insulin-like growth factor-I)
    Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ-1
  • Intrauterine growth retardation
    Àڱó» ¹ßÀ° Áö¿¬ (í­ÏàÒ® Û¡ëÀ òÀæÅ)
  • NGF=>nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • T cell growth factor (TCGF, IL-2)
    T¼¼Æ÷ Áõ½ÄÀÎÀÚ
  • T-cell growth factor
    T-¼¼Æ÷¼ºÀåÀÎÀÚ
  • TGF => transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • abnormal growth
    ºñÁ¤»ó¼ºÀå
  • anomalous growth
    ÀÌ»ó¼ºÀå.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • iridocorneal-endothelial syndrome
    ȫä°¢¸·³»ÇÇÁõÈıº
  • nonfenestrated endothelial cell
    ¹Îâ³»ÇǼ¼Æ÷
  • papillary endothelial hyperplasia
    À¯µÎ ³»ÇǼ¼Æ÷ Áõ½Ä
  • platelet endothelial cell adhesion molecule 1(pecam-1)
    Ç÷¼ÒÆÇ³»ÇǼ¼Æ÷ºÐÀÚ(úìá³÷ùÒ®ù«á¬øàÝÂí­)1
  • articular vascular network
    °üÀý¸Æ°ü±×¹°
  • cerebral vascular accident =CVA
    ³úÇ÷°ü»ç°í.
  • cerebral vascular disease
    ³úÇ÷°üÁúȯ.
  • collagen-vascular disease
    ±³¿ø-Ç÷°ü Áúȯ
  • collagen-vascular disorders
    ÄݶóÁ¨-Ç÷°üÁúȯ(¡­úìηòðü´)
  • concentric vascular bundle
    ÁýÁß(µ¿½É¼º) ¸Æ°ü´Ù¹ß.
  • coronary vascular resistance =CVR
    °ü(»ó)Ç÷°üÀúÇ×(¡­úìηî½ù÷).
  • ectasia, vascular
    È®ÀåÁõ, Ç÷°ü(¼º)
  • edema,increased vascular permeability
    Ç÷°üÅõ°ú¼ºÁõ°¡(úìη÷âΦàõñòÊ¥)
  • endothelium, primitive vascular
  • endothelium,vascular
    Ç÷°ü¼º(úìηàõ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Vascular placenta
    Ç÷°üŹÝ
    [¿¾ ¿ë¾î] Ç÷°ü¼ºÅ¹Ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • step-growth polymer
    ´Ü°è¼ºÀå ÁßÇÕü(Ó«Í­à÷íþñìùêô÷)
  • synchronous growth
    µ¿±â¼ºÀå (ÔÒÑ¢à÷íþ)
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • unbalanced growth
    ºÒ±ÕÇü(ÝÕгû¬) ¼ºÀå (à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PVR peripheral vascular resistance; perspective volume rendering; poliovirus receptor; postvoiding resid...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SVR sequential vascular response; systemic vascular resistance
TPVR total peripheral vascular resistance; total pulmonary vascular resistance
ANF Atrial Natriuretic Factors
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
VEGF(165) vascular endothelial growth factor
EGFR Epidermal growth factors receptor
GF Growth Factors
GDF Growth and differentiation factors
HGF Hemopoietic growth factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prenatal facial growth
    Ãâ»ýÀüÀÇ ¾ó±¼ ¼ºÀå
  • proliferative growth
    Áõ½Ä¼º ¼ºÀå
  • retardation of growth
    ¼ºÀå Áö¿¬
  • somatic growth
    ½ÅüÇü ¼ºÀå, ü¼º ¼ºÀå
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • too much growth
    Áõ½Ä
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vertical growth
    ¼öÁ÷ ¼ºÀå
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • cerebral vascular disease
    ³ú Ç÷°ü Áúȯ
  • collagen-vascular disease
    ±³¿øÁú-Ç÷°ü¼º Áúȯ
  • hepatic vascular resistance
    °£ Ç÷°ü ÀúÇ×
  • mixed muscular vascular headache
    ±Ù¸Æ°ü¼º È¥ÇÕ µÎÅë, È¥ÇÕµÈ ±Ù-Ç÷°ü¼º µÎÅë, È¥ÇÕ¼º ±ÙÀ° Ç÷°ü µÎÅë, È¥ÇÕÇü ±Ù¸Æ°ü¼º µÎÅë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
recognition factors Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites.
(05 Mar 2000)
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
releasing factors Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland.
(09 Oct 1997)
resistance factors Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter.
Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes.
(05 Mar 2000)
peptide elongation factors Protein factors uniquely required during the elongation phase of protein synthesis.
(12 Dec 1998)
peptide initiation factors Protein factors uniquely required during the initiation phase of protein synthesis.
(12 Dec 1998)
peptide termination factors Proteins that are exclusively involved in the termination reactions of protein synthesis on the ribosome.
(12 Dec 1998)
C factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
r factors A class of plasmids that transfer antibiotic resistance from one bacterium to another by conjugation.
(12 Dec 1998)
rheumatoid factors Antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma-globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases.
(05 Mar 2000)
chemotactic factors Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult.
(12 Dec 1998)
chemotactic factors, eosinophil Cytotaxins liberated from normal or invading cells that specifically attract eosinophils; they may be complement fragments, lymphokines, neutrophil products, histamine or other; the best known is the tetrapeptide ecf-a, released mainly by mast cells.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
meteorological factors The atmospheric phenomena which pertain to climate and weather.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á